Rafael
De la Torre Fornell
![Foto de Rafael](/img/nophoto.png)
![Foto de Centro de Investigación Biomédica en Red sobre Enfermedades Raras](/img/noimage_org.png)
Centro de Investigación Biomédica en Red sobre Enfermedades Raras
Madrid, EspañaPublicacións en colaboración con investigadores/as de Centro de Investigación Biomédica en Red sobre Enfermedades Raras (10)
2024
2021
-
Comparison of covid‐19 and non‐covid‐19 pneumonia in down syndrome
Journal of Clinical Medicine, Vol. 10, Núm. 16
-
Green tea extracts containing epigallocatechin-3-gallate modulate facial development in Down syndrome
Scientific Reports, Vol. 11, Núm. 1
2020
-
A phase 1, randomized double-blind, placebo controlled trial to evaluate safety and efficacy of epigallocatechin-3-gallate and cognitive training in adults with Fragile X syndrome
Clinical Nutrition, Vol. 39, Núm. 2, pp. 378-387
2017
-
Anomalous White Matter Structure and the Effect of Age in Down Syndrome Patients
Journal of Alzheimer's Disease, Vol. 57, Núm. 1, pp. 61-70
-
Potential role of (-)-epigallocatechin-3-gallate (EGCG) in the secondary prevention of Alzheimer disease
Current Drug Targets, Vol. 18, Núm. 2, pp. 174-195
2015
-
A new cognitive evaluation battery for Down syndrome and its relevance for clinical trials
Frontiers in Psychology, Vol. 6, Núm. JUN
-
Potential role of olive oil phenolic compounds in the prevention of neurodegenerative diseases
Molecules, Vol. 20, Núm. 3, pp. 4655-4680
-
Semantic verbal fluency pattern, dementia rating scores and adaptive behavior correlate with plasma Aβ42concentrations in down syndrome young adults
Frontiers in Behavioral Neuroscience, Vol. 9, Núm. NOVEMBER
2013
-
Targeting the endocannabinoid system in the treatment of fragile X syndrome
Nature Medicine, Vol. 19, Núm. 5, pp. 603-607